SCHOLAR ROCK HOLDING CORP (SRRK)
Health Care · Rare neuromuscular disease biopharmaceuticals / myostatin inhibitors · NASDAQ
Scholar Rock develops myostatin-inhibiting monoclonal antibodies to treat rare neuromuscular diseases like spinal muscular atrophy, with lead candidate apitegromab anticipated for regulatory approval in 2026.
What SCHOLAR ROCK HOLDING CORP does
Scholar Rock is a biopharmaceutical company focused on developing monoclonal antibodies that target latent forms of growth factors, particularly myostatin inhibitors, for rare neuromuscular diseases. The company's lead candidate, apitegromab, is a novel myostatin inhibitor in late-stage development for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). Scholar Rock is transitioning from a clinical-stage to a commercial-stage organization with anticipated regulatory approvals for apitegromab in the U.S. and Europe in 2026.
Themes: ["Myostatin inhibition / muscle atrophy","Spinal muscular atrophy (SMA)","Rare neuromuscular diseases","TGFβ superfamily biology","Monoclonal antibodies","Lean mass preservation / weight loss combinations"]
Fundamentals
- Price$57.94 as of 2026-07-09 close
- Market cap$6.9B as of 2026-07-10
- 1-year return+56.6% as of 2026-07-09 close
- Net margin-237.0% as of 2026-07-10
- ROE-162.9% as of 2026-07-10
- Debt / equity0.71 as of 2026-07-10
- Beta0.64 as of 2026-07-10
Key risks (from latest filing)
["Regulatory approval risk: Received FDA Complete Response Letter in September 2025 for apitegromab BLA; resubmission accepted in March 2026 but additional FDA review and potential further delays remain uncertain, and EMA review could also be impacted.","Commercialization execution risk: Company has never commercialized a product and is building compliance, medical affairs, and commercial organizations for apitegromab launch; failure to execute successfully could negatively impact revenue potential.","EU pricing and reimbursement risk: Unfavorable pricing decisions, restricted reimbursement, mandatory discounts, or denial of coverage by EU health technology assessment bodies and national payors could significantly delay patient access and materially reduce anticipated revenues."]
Competitors & peers
- Biogen (BIIB) - SMA therapies (nusinersen, onasemnogene abeparvovec, risdiplam)
- Roche/Genentech - SMA and neuromuscular disease focus
- AveXis (acquired by Novartis) - gene therapy for SMA
- Sesen Bio - rare disease antibody therapies
- Grifols - neuromuscular disease treatments
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.